文献速递腹部介入CTMR

肝细胞癌肝移植患者中新辅助治疗后mRECIST的跨中心一致性评估

Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma.
PubMed 文献 · Eur Radiol · 2021-06-12

研究纳入3个专家中心对90例肝细胞癌患者肝移植前新辅助治疗前后共180次影像检查的回顾性阅片,评估mRECIST及肿瘤数目、大小、移植标准的观察者间一致性。mRECIST一致性的kappa为0.648(substantial),新辅助治疗前MRI的ICC(0.657-0.899)高于CT(0.422-0.776)。影像学完全缓解对病理完全缓解的阳性预测值仅51.6%。

要点

  • mRECIST跨观察者一致性为substantial(kappa=0.648), concordant pairs 201/270(76.3%)。
  • 新辅助治疗前肿瘤数目、大小及移植标准一致性中等至几乎完美,MRI的ICC高于CT。
  • 新辅助治疗后一致性下降;影像学CR对病理CR的阳性预测值仅51.6%。

核心结论

  • 三观察者间mRECIST一致性为substantial;肿瘤数目、大小及移植标准一致性中等至几乎完美,新辅助治疗前MRI的ICC最高;mRECIST预测病理完全缓解的效能仅为fair。

研究设计与样本

  • 回顾性研究,纳入3个专家中心90例肝细胞癌患者肝移植前新辅助治疗前后共180次影像检查,评估mRECIST及肿瘤特征的一致性,以病理为参考标准比较影像学完全缓解与病理完全缓解。

诊断标准与关键数值

  • mRECIST一致性: concordant pairs 201/270(76.3%),kappa=0.648,为substantial agreement。
  • 新辅助治疗前肿瘤数目、大小及移植标准ICC范围从moderate(ICC 0.41-0.60)到almost perfect(ICC 0.81-0.99);MRI的ICC为0.657-0.899,CT为0.422-0.776。
  • 新辅助治疗后ICC下降:MRI为0.518-0.663,CT为0.508-0.677。
  • 三观察者完全一致判定CR时,对病理完全缓解的阳性预测值为51.6%;阴性预测值为94.2%,kappa=0.512,影像与病理一致性为fair。

临床应用与阅片要点

  • 新辅助治疗前MRI对肿瘤数目、大小及移植标准的一致性最高(ICC 0.657-0.899),高于CT(ICC 0.422-0.776)。
  • 新辅助治疗后CT及局部治疗后评估移植标准的一致性略有下降(ICC 0.508-0.677)。
  • 影像学判定完全缓解对病理完全缓解的阳性预测值仅51.6%,阴性预测值94.2%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the inter-observer reliability of modified Response Evaluation Criteria In Solid Tumours (mRECIST) of patients with hepatocellular carcinoma (HCC) undergoing neo-adjuvant treatments before liver transplant (LT). The agreement of tumor number, size, transplant criteria, and the radiological-pathological concordance were also assessed.

METHODS: A total of 180 radiological studies before/after neo-adjuvant therapies performed on 90 patients prior to LT were reviewed from three expert centers. Kappa-statistic and intraclass correlation (ICC) were evaluated on mRECIST and on tumoral features. Complete radiological response (CR) was compared with complete pathological response (CPR).

RESULTS: Before neo-adjuvant therapies, the agreement on tumor number, size, and transplant criteria ranged from moderate (defined as ICC of 0.41-0.60) to almost perfect (ICC of 0.81-0.99), being higher with magnetic resonance imaging (MRI) than CT (0.657-0.899 and 0.422-0.776, respectively). After neo-adjuvant therapies, the agreement decreased, as ICCs ranged between 0.518 and 0.663 with MRI and between 0.508 and 0.677 with CT. Concordant mRECIST pairs were 201 of 270 reviews (76.3%) with a kappa of 0.648 indicating substantial agreement. When the three observers completely agreed on CR, the positive predictive value for CPR was 51.6%. The negative predictive value was 94.2% with a kappa of 0.512 indicating fair agreement between radiology and pathology.

CONCLUSIONS: mRECIST agreement was substantial among the three observers involved. The agreement on tumor number, size, and transplant criteria ranged from moderate to almost perfect, with the highest ICCs obtained with MRI before neo-adjuvant therapies. Finally, the predictive value of mRECIST in the diagnosis of CPR was only fair.

KEY POINTS: • The review of 180 radiological exams of patients with hepatocellular carcinoma before and after neo-adjuvant therapies showed that the concordance among three different raters on mRECIST diagnosis was substantial. • The inter-observer reliability on fulfilment of transplant criteria slightly decreased when evaluated through CT and after loco-regional therapies. • The radiological diagnosis of complete response after neo-adjuvant therapies was predictive of complete pathological response in only 51.6% of cases.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Vicentin I, Mosconi C, Garanzini E, et al. Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. Eur Radiol. 2021. PMID: 34117911. doi:10.1007/s00330-021-08088-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。